Thermo Fisher Scientific Inc. (NYSE: TMO), Waltham, MA, has agreed to acquire Brammer Bio for $1.7 billion. The acquisition would expand the lab-equipment company’s presence in the field of gene therapy.
Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drug making services.
Brammer Bio was formed in 2016 through the merger of Brammer Biopharmaceuticals and Florida Biologix.
© 2019 Gale Media, Inc.
Please do not reprint MDM's content on your website without MDM's express permission as it is copyrighted material. To gain permission, email us, or call 1-888-742-5060. For information on PDF or print reprints, visit www.mdm.com/reprints. MDM welcomes inbound links from your site. Please cite Modern Distribution Management.
The 2018 Top Distributors List
This free PDF includes lists of top distribution companies across 14 sectors.
You will also receive MDM Update, our daily distribution e-newsletter & other distribution-focused content.
Download the Free PDF now >>
MDM Update: Daily Newsletter
Sign up to read the best source for news & trends in wholesale distribution, MDM Update. Delivered daily to your inbox.
Sign-up for MDM Update >>